News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
242,339 Results
Type
Article (9723)
Company Profile (125)
Press Release (232484)
Multimedia
Podcasts (74)
Webinars (11)
Section
Business (69145)
Career Advice (515)
Deals (13631)
Drug Delivery (36)
Drug Development (40116)
Employer Resources (75)
FDA (4662)
Job Trends (5431)
News (125624)
Policy (9279)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Pharm Country Standard (1)
Academia (490)
Accelerated approval (14)
Adcomms (4)
Allergies (73)
Alliances (16302)
ALS (97)
Alzheimer's disease (781)
Antibody-drug conjugate (ADC) (219)
Approvals (4976)
Artificial intelligence (321)
Autoimmune disease (103)
Automation (23)
Bankruptcy (75)
Best Places to Work (4470)
BIOSECURE Act (16)
Biosimilars (114)
Biotechnology (81)
Bladder cancer (105)
Brain cancer (31)
Breast cancer (403)
Cancer (3039)
Cardiovascular disease (207)
Career advice (470)
Career pathing (28)
CAR-T (160)
CDC (14)
Cell therapy (383)
Cervical cancer (21)
Clinical research (36301)
Collaboration (1114)
Company closure (1)
Compensation (832)
Complete response letters (24)
COVID-19 (959)
CRISPR (51)
C-suite (553)
Cystic fibrosis (72)
Data (4046)
Decentralized trials (1)
Denatured (13)
Depression (77)
Diabetes (215)
Diagnostics (1558)
Digital health (20)
Diversity (8)
Diversity, equity & inclusion (20)
Drug discovery (145)
Drug pricing (67)
Drug shortages (4)
Duchenne muscular dystrophy (115)
Earnings (33663)
Editorial (40)
Employer branding (10)
Employer resources (65)
Events (45436)
Executive appointments (674)
FDA (6539)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (2)
Frontotemporal dementia (12)
Funding (832)
Gene editing (102)
Generative AI (27)
Gene therapy (277)
GLP-1 (418)
Government (1189)
Grass and pollen (5)
Guidances (254)
Healthcare (4208)
HIV (31)
Huntington's disease (19)
IgA nephropathy (54)
Immunology and inflammation (117)
Immuno-oncology (44)
Indications (63)
Infectious disease (1078)
Inflammatory bowel disease (95)
Inflation Reduction Act (9)
Influenza (41)
Intellectual property (132)
Interviews (79)
IPO (7328)
IRA (19)
Job creations (1157)
Job search strategy (382)
JPM (34)
Kidney cancer (9)
Labor market (74)
Layoffs (195)
Leadership (28)
Legal (1326)
Liver cancer (51)
Longevity (5)
Lung cancer (457)
Lymphoma (245)
Machine learning (25)
Management (23)
Manufacturing (426)
MASH (120)
Medical device (1949)
Medtech (1966)
Mergers & acquisitions (7099)
Metabolic disorders (610)
Multiple sclerosis (102)
NASH (9)
Neurodegenerative disease (156)
Neuropsychiatric disorders (45)
Neuroscience (1470)
NextGen: Class of 2026 (1484)
Non-profit (622)
Now hiring (52)
Obesity (263)
Opinion (125)
Ovarian cancer (87)
Pain (94)
Pancreatic cancer (134)
Parkinson's disease (144)
Partnered (7)
Patents (242)
Patient recruitment (306)
Peanut (32)
People (21657)
Pharmaceutical (39)
Pharmacy benefit managers (8)
Phase 1 (11156)
Phase 2 (16318)
Phase 3 (12262)
Pipeline (3376)
Policy (133)
Postmarket research (847)
Preclinical (4434)
Press Release (26)
Prostate cancer (137)
Psychedelics (20)
Radiopharmaceuticals (157)
Rare diseases (469)
Real estate (1494)
Recruiting (33)
Regulatory (9109)
Reports (34)
Research institute (562)
Resumes & cover letters (64)
Rett syndrome (25)
RNA editing (5)
RSV (37)
Schizophrenia (115)
Series A (133)
Series B (114)
Service/supplier (5)
Sickle cell disease (54)
Special edition (23)
Spinal muscular atrophy (64)
Sponsored (11)
Startups (1206)
State (1)
Stomach cancer (4)
Supply chain (51)
Tariffs (49)
The Weekly (60)
Vaccines (372)
Venture capital (54)
Weight loss (118)
Women's health (39)
Worklife (15)
Date
Today (84)
Last 7 days (358)
Last 30 days (1304)
Last 365 days (18730)
2026 (1876)
2025 (18898)
2024 (17785)
2023 (18320)
2022 (21185)
2021 (22621)
2020 (20066)
2019 (13934)
2018 (10296)
2017 (11820)
2016 (9882)
2015 (12279)
2014 (9160)
2013 (6597)
2012 (6537)
2011 (6570)
2010 (6208)
Location
Africa (247)
Alabama (32)
Arizona (52)
Arkansas (5)
Asia (17843)
Australia (2301)
California (7242)
Canada (1560)
China (874)
Colorado (253)
Connecticut (324)
Delaware (277)
Europe (35867)
Florida (840)
Georgia (173)
Hawaii (3)
Idaho (26)
Illinois (435)
India (37)
Indiana (213)
Iowa (20)
Japan (344)
Kansas (74)
Kentucky (14)
Louisiana (6)
Maine (6)
Maryland (675)
Massachusetts (5531)
Michigan (112)
Minnesota (276)
Mississippi (2)
Missouri (55)
Montana (2)
Nebraska (8)
Nevada (80)
New Hampshire (21)
New Jersey (2051)
New Mexico (12)
New York (1945)
North Carolina (793)
North Dakota (3)
Northern California (3576)
Ohio (198)
Oklahoma (10)
Oregon (18)
Pennsylvania (1157)
Puerto Rico (14)
Rhode Island (19)
South America (341)
South Carolina (8)
Southern California (2836)
Tennessee (109)
Texas (952)
United States (24083)
Utah (134)
Virginia (153)
Washington D.C. (45)
Washington State (523)
West Virginia (3)
Wisconsin (95)
Wyoming (1)
242,339 Results for "syner g biopharma group.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Kristin Murray Joins Syner-G BioPharma Group as Senior Vice President of Regulatory Services
Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients
May 24, 2024
·
1 min read
Syner-G BioPharma Group Named A BioSpace 2024 Best Places to Work Winner
yner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to pharmaceutical and biotechnology clients
May 24, 2024
·
2 min read
Career Advice
The Top 12 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the
BioSpace
list of 12 top companies hiring life sciences professionals like you.
February 5, 2026
·
1 min read
·
Angela Gabriel
Syner-G Biopharma Group Announces Karen Casey as Chief People Officer
January 10, 2023, Boston, MA — Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to the pharmaceutical and medical device industries, today announced that Karen Casey has joined the organization as the chief people officer.
August 11, 2023
·
1 min read
Job Trends
Hiring Plans Show Promise for Biopharma Job Seekers:
BioSpace
Report
More biopharma organizations were actively recruiting at the end of 2025 than 2024, based on the new
BioSpace
employment outlook report. Areas in demand this year include research and development and clinical. Organizations are also prioritizing artificial intelligence hires.
January 29, 2026
·
5 min read
·
Angela Gabriel
JPM
JPM26: Biopharma Projected Positivity in San Francisco. Now It’s Time To Execute
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
January 27, 2026
·
6 min read
·
Annalee Armstrong
Press Releases
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
January 5, 2026
·
17 min read
Drug Development
Biopharma Momentum To Propel Rare Disease, Cancer, Neuro Forward in 2026
After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told
BioSpace
, with both rare and chronic diseases headlining investor and R&D interest as JPM26 kicks off.
January 12, 2026
·
6 min read
·
Heather McKenzie
Layoffs
Biopharmas Axed 47% More Employees Year Over Year
In 2025, made or projected biopharma workforce cuts affected about 42,700 employees, according to
BioSpace
tallies.
BioSpace
takes a deep dive into which companies and locations were impacted and speaks to experts about what to expect ahead—and why.
January 8, 2026
·
5 min read
·
Angela Gabriel
Opinion
A Flu Season in Flux Presents Risks, Opportunities for Biopharma
The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, prevention and portfolio structure are no longer guaranteed.
October 28, 2025
·
7 min read
·
Tom Sebok
1 of 24,234
Next
